Adina Pelusio

1.1k total citations
6 papers, 331 citations indexed

About

Adina Pelusio is a scholar working on Genetics, Biotechnology and Oncology. According to data from OpenAlex, Adina Pelusio has authored 6 papers receiving a total of 331 indexed citations (citations by other indexed papers that have themselves been cited), including 5 papers in Genetics, 4 papers in Biotechnology and 3 papers in Oncology. Recurrent topics in Adina Pelusio's work include Virus-based gene therapy research (5 papers), Cancer Research and Treatments (4 papers) and CAR-T cell therapy research (3 papers). Adina Pelusio is often cited by papers focused on Virus-based gene therapy research (5 papers), Cancer Research and Treatments (4 papers) and CAR-T cell therapy research (3 papers). Adina Pelusio collaborates with scholars based in South Korea, United States and Taiwan. Adina Pelusio's co-authors include James M. Burke, Caroline J. Breitbach, Anne Moon, David H. Kirn, Young Suk Park, Jeeyun Lee, Ho Yeong Lim, Se Hoon Park, Won Ki Kang and Joon Oh Park and has published in prestigious journals such as Journal of Clinical Oncology, Molecular Therapy and Liver Cancer.

In The Last Decade

Adina Pelusio

6 papers receiving 327 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Adina Pelusio South Korea	5	233	232	102	88	56	6	331
Nathalie Silvestre France	11	167 0.7×	188 0.8×	127 1.2×	181 2.1×	34 0.6×	32	428
Marina Duarte Spain	11	230 1.0×	189 0.8×	321 3.1×	158 1.8×	60 1.1×	13	531
Naomi De Silva Canada	8	357 1.5×	431 1.9×	122 1.2×	198 2.3×	110 2.0×	10	520
Joanna Poutou Spain	10	95 0.4×	111 0.5×	50 0.5×	115 1.3×	25 0.4×	17	231
Céline Halluard France	4	133 0.6×	79 0.3×	145 1.4×	118 1.3×	23 0.4×	7	303
Ibrahim Ragab Eissa Japan	8	190 0.8×	198 0.9×	69 0.7×	123 1.4×	57 1.0×	12	307
Kathryn Ottolino‐Perry Canada	8	178 0.8×	263 1.1×	34 0.3×	105 1.2×	81 1.4×	9	353
Il-Kyu Choi South Korea	7	291 1.2×	269 1.2×	145 1.4×	177 2.0×	71 1.3×	7	435
Bala Sai Sundarasetty Germany	13	162 0.7×	119 0.5×	171 1.7×	103 1.2×	11 0.2×	14	279
An-Dao Yang Canada	4	148 0.6×	285 1.2×	51 0.5×	140 1.6×	53 0.9×	6	363

Countries citing papers authored by Adina Pelusio

Since Specialization

Citations

This map shows the geographic impact of Adina Pelusio's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Adina Pelusio with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Adina Pelusio more than expected).

Fields of papers citing papers by Adina Pelusio

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Adina Pelusio. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Adina Pelusio. The network helps show where Adina Pelusio may publish in the future.

Co-authorship network of co-authors of Adina Pelusio

This figure shows the co-authorship network connecting the top 25 collaborators of Adina Pelusio. A scholar is included among the top collaborators of Adina Pelusio based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Adina Pelusio. Adina Pelusio is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

6 of 6 papers shown

Abou‐Alfa, Ghassan K., Peter R. Galle, Yee Chao, et al.. (2023). PHOCUS: A Phase 3, Randomized, Open-Label Study of Sequential Treatment with Pexa-Vec (JX-594) and Sorafenib in Patients with Advanced Hepatocellular Carcinoma. Liver Cancer. 13(3). 256–272. 23 indexed citations

Ha, Hong Koo, Sung-Nam Lim, Adina Pelusio, et al.. (2018). Phase II trial of pexa-vec (pexastimogene devacirepvec; JX-594), an oncolytic and immunotherapeutic vaccinia virus, in patients with metastatic, refractory renal cell carcinoma (RCC).. Journal of Clinical Oncology. 36(6_suppl). 671–671. 7 indexed citations

Abou‐Alfa, Ghassan K., Peter R. Galle, Yee Chao, et al.. (2016). PHOCUS: A phase 3 randomized, open-label study comparing the oncolytic immunotherapy Pexa-Vec followed by sorafenib (SOR) vs SOR in patients with advanced hepatocellular carcinoma (HCC) without prior systemic therapy.. Journal of Clinical Oncology. 34(15_suppl). TPS4146–TPS4146. 33 indexed citations

Park, Se Hoon, Caroline J. Breitbach, Jeeyun Lee, et al.. (2015). Phase 1b Trial of Biweekly Intravenous Pexa-Vec (JX-594), an Oncolytic and Immunotherapeutic Vaccinia Virus in Colorectal Cancer. Molecular Therapy. 23(9). 1532–1540. 140 indexed citations

Cripe, Timothy P., Minhtran Ngo, James I. Geller, et al.. (2014). Phase 1 Study of Intratumoral Pexa-Vec (JX-594), an Oncolytic and Immunotherapeutic Vaccinia Virus, in Pediatric Cancer Patients. Molecular Therapy. 23(3). 602–608. 125 indexed citations

Lee, Jeeyun, Young Suk Park, James M. Burke, et al.. (2013). Phase Ib dose-escalation study of Pexa-Vec (pexastimogene devacirepvec; JX-594), an oncolytic and immunotherapeutic vaccinia virus, administered by intravenous (IV) infusions in patients with metastatic colorectal carcinoma (mCRC).. Journal of Clinical Oncology. 31(15_suppl). 3608–3608. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact